The bio-pharmaceutical industry has emerged as a key strategic sector in Taicang, with the Biopharmaceutical Industrial Park in Shaxi town rapidly expanding.

By the end of 2024, the number of biomedical companies in the park surged by 167 percent, reaching 482. Meanwhile, the park covered a total area of over 1.02 million square meters, with another 460,000 sq m now under construction.

Corporations in the park have demonstrated remarkable growth. Salubris (Suzhou) Pharmaceutical Co was one of the first companies to set up operations here. In 2019, the teriparatide injection developed by the company gained regulatory approval, marking the first new drug incubated in the park to enter the market. This year, its upgraded version is projected to generate 250 million yuan ($35.11 million) in revenue.

In recent years, the park has welcomed dozens of bio-pharmaceutical enterprises with strong innovation capabilities and enormous development potential. Such efforts have advanced the development of the park into "Taicang Drug Valley".

An aerial view of the Biopharmaceutical Industrial Park in Taicang. [Photo/WeChat account: tcfbgw]